GLS and gastric cancer: Cancer cells use CDC42 to release GLS1‐containing vesicles, boosting glutamine metabolism, and promoting M2 macrophage polarization. This process aids macrophage‐mediated angiogenesis and contributes to trastuzumab resistance in HER2‐positive gastric cancer